AstraZeneca drugmaker to cut 1,600 jobs

• Published March 19, 2013

  • 0 comments

Struggling Anglo-Swedish drugmaker AstraZeneca PLC said Monday that it will eliminate 1,600 jobs, mostly in the U.S. and United Kingdom, as its new CEO starts a major research and development reorganization.

The cuts, meant to reduce costs and make research programs more productive, come just weeks after the company reported big drops in revenue and net income for 2012 and forecast continuing difficulties as generic competition hurts sales.

The job reductions amount to nearly 3 percent of AstraZeneca’s 57,200 workers worldwide. In January, AstraZeneca said generic competition in Western Europe and other areas was slashing sales of top sellers including Nexium for severe heartburn, Seroquel IR for schizophrenia and Crestor for high cholesterol.

Similar stories:

  • On the Money: Better ways to search online for a job

  • Hiring slows sharply in March, jobless rate dips

  • Researchers at UW fear federal cuts will hit hard

  • Washington state unemployment rate falls to 7 percent

  • Unemployment falls in 40 US states, rises in 3

COMMENTS Community Publishing Guidelines

Join the Reader Network

Do you want The Olympian to keep you in mind when we canvass the community for opinions?

Click here and sign up with our Reader Network to offer your view.